Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems

Executive Summary

Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.

You may also be interested in...



Schering-Plough To Pay $165 Million To Shareholders For Clarinex Delay

The company is settling claims it failed to reveal that negative FDA inspection reports would delay approval of its allergy medicine.

Schering Clarinex Approval Comes In Time For Big Spring Push

Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season

Schering Clarinex Approval Comes In Time For Big Spring Push

Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season

Related Content

UsernamePublicRestriction

Register

PS037376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel